Cagrilintide

Amylin-pathway support designed to encourage appetite regulation and sustainable weight
management.

Cagrilintide is a long-acting amylin analogue that supports satiety and appetite regulation through a biologicalpathway distinct from GLP-1 medications. For clients already using Semaglutide or Tirzepatide, Cagrilintide offers acomplementary mechanism that supports the same goal from a different angle.

Calibrate IV providers introduce Cagrilintide as part of a physician-guided metabolic strategy when appetite control and satiety remain priority goals. It is typically incorporated as a layered approach to weight management rather than
a standalone intervention.

Key Benefits
• Designed to encourage appetite regulation and a greater sense of satiety
• Complements physician-guided GLP-1-based weight programs
• Plays a role in supporting gradual, sustainable weight management
• Works through a pathway that is mechanistically distinct from GLP-1 / GIP

Ideal For Clients already on a Calibrate IV weight program who want to broaden satiety support and individuals whose providers have identified appetite regulation as a priority lever.

Treatment Protocol
Frequency Dose Cycle
Weekly 0.5–2.4 mg, titrated Ongoing program